Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Isolated limb perfusion for melanoma.

Bin B R Kroon1, Eva M Noorda, Bart C Vrouenraets

  • 1Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, the Netherlands. b.kroon@nki.nl

Surgical Oncology Clinics of North America
|August 30, 2008
PubMed
Summary

High-dose chemotherapy isolated limb perfusion, often with melphalan and tumor necrosis factor-alpha, offers locoregional control for advanced extremity melanoma. Repeat perfusions may benefit recurrent cases, with mild temperatures showing comparable results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma.

Journal of the National Cancer Institute·2026
Same author

Timing of Definitive Surgical Management of Primary Cutaneous Melanoma: Association With Survival.

ANZ journal of surgery·2026
Same author

Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patients.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

ASO Visual Abstract: Cartilage Resection in the Surgical Management of Ear Melanoma.

Annals of surgical oncology·2025
Same author

Cartilage Resection in the Surgical Management of Ear Melanoma.

Annals of surgical oncology·2025
Same author

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma.

JAMA dermatology·2025

Area of Science:

  • Oncology
  • Surgical Oncology
  • Pharmacology

Background:

  • Advanced melanoma of the extremities presents a challenge for locoregional control.
  • Isolated limb perfusion (ILP) with high-dose chemotherapy is an established treatment.
  • Melphalan is the primary chemotherapeutic agent used in ILP.

Purpose of the Study:

  • To evaluate the efficacy and safety of ILP for advanced and recurrent melanoma of the extremities.
  • To assess the role of tumor necrosis factor-alpha in combination with melphalan.
  • To determine the impact of perfusion temperature and adjuvant use in specific melanoma scenarios.

Main Methods:

  • Isolated limb perfusion with high-dose melphalan, often combined with tumor necrosis factor-alpha.
  • Comparison of perfusion outcomes at mild hyperthermic (37-38°C) versus normothermic temperatures.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Related Experiment Videos

Last Updated: Jul 2, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

  • Analysis of ILP as an adjuvant to wide local excision and for repeat perfusions in recurrent melanoma.

    • Main Results:

    • ILP with melphalan provides locoregional control for advanced extremity melanoma.
    • Combining melphalan with tumor necrosis factor-alpha is a viable option for recurrent disease after prior perfusion.
    • Perfusion at 37-38°C yielded results comparable to mild hyperthermic conditions.
    • Adjuvant ILP in primary melanoma is not recommended.
    • Adjuvant ILP for repeatedly recurrent limb melanoma improved recurrence-free interval and reduced lesion burden.

    Conclusions:

    • Isolated limb perfusion is effective for locoregional control in advanced and recurrent extremity melanoma.
    • Repeat perfusions and mild temperature perfusions are viable options.
    • ILP should not be used as an adjunct for primary melanoma but shows benefit in select recurrent cases.
    • Regional toxicity is manageable when risk factors are considered.